Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

Carbapenem‐resistant Acinetobacter baumannii (CRAB) is a difficult‐to‐treat nosocomial
pathogen responsible for significant morbidity and mortality. Sulbactam‐durlobactam (SUL …

Eravacycline is a synthetic fluorocycline approved by the US Food and Drug Administration
in 2018. This study aimed to describe clinical and microbiological outcomes in addition to …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are
associated with high mortality rates. The optimal treatment regimen for CRAB has not been …

It is estimated that antimicrobial resistance (AMR) is responsible for nearly 5 million human
deaths worldwide each year and will reach 10 million by 2050. Carbapenem-resistant …

The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter
baumannii with emerging cefiderocol resistance remains challenging and unclear. We …

Introduction Several novel agents are in advanced stages of clinical development,
potentially expanding our treatment options against third-and fourth-generation …

Infections due to Acinetobacter spp. are among the most difficult to treat. Most are resistant to
standard antibiotics, and there is difficulty in distinguishing colonizers from pathogens. This …

Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a
clinical challenge due to limited treatment options. Recently, cefiderocol, a novel …

ABSTRACT Introduction Acinetobacter baumannii complex (Abc) is currently a significant
cause of difficult-to-treat pneumonia. Due to the high prevalence rates of carbapenem-and …